- Home
- DVAX vs SBGI Comparison
DVAX vs SBGI Comparison
Compare DVAX & SBGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- SBGI
- Stock Information
- Founded
- DVAX 1996
- SBGI 1986
- Country
- DVAX United States
- SBGI United States
- Employees
- DVAX N/A
- SBGI N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- SBGI Broadcasting
- Sector
- DVAX Health Care
- SBGI Industrials
- Exchange
- DVAX Nasdaq
- SBGI Nasdaq
- Market Cap
- DVAX 1.2B
- SBGI 970.9M
- IPO Year
- DVAX 2004
- SBGI 1995
- Fundamental
- Price
- DVAX $10.15
- SBGI $14.18
- Analyst Decision
- DVAX Buy
- SBGI Buy
- Analyst Count
- DVAX 4
- SBGI 5
- Target Price
- DVAX $26.50
- SBGI $20.80
- AVG Volume (30 Days)
- DVAX 1.7M
- SBGI 477.1K
- Earning Date
- DVAX 11-06-2025
- SBGI 11-05-2025
- Dividend Yield
- DVAX N/A
- SBGI 7.09%
- EPS Growth
- DVAX N/A
- SBGI N/A
- EPS
- DVAX N/A
- SBGI 0.74
- Revenue
- DVAX $316,268,000.00
- SBGI $3,481,000,000.00
- Revenue This Year
- DVAX $23.23
- SBGI N/A
- Revenue Next Year
- DVAX $16.57
- SBGI $9.50
- P/E Ratio
- DVAX N/A
- SBGI $19.03
- Revenue Growth
- DVAX 26.66
- SBGI 8.11
- 52 Week Low
- DVAX $9.20
- SBGI $11.89
- 52 Week High
- DVAX $14.63
- SBGI $18.46
- Technical
- Relative Strength Index (RSI)
- DVAX 52.11
- SBGI 46.09
- Support Level
- DVAX $9.95
- SBGI $14.44
- Resistance Level
- DVAX $10.35
- SBGI $15.45
- Average True Range (ATR)
- DVAX 0.29
- SBGI 0.46
- MACD
- DVAX 0.08
- SBGI -0.05
- Stochastic Oscillator
- DVAX 75.00
- SBGI 17.70
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.